Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|January 15, 2002

BioPharm International

  • BioPharm International-01-01-2002
  • Volume 15
  • Issue 1

Liposomes (a Review): Part Two, Drug Delivery Systems

by Suggy S. Chrai, R. Murari, and Imran Ahmad Good manufacturing processes require that lipid vesicles be reproducibly uniform in size, carry the drug in sufficient concentration, and remain stable for an acceptable shelf-life under varying temperatures. Following these guidelines improves the analytical processes that support biopharmaceutical drug development.
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

almost 25 years ago

Outsourcing Outlook: E-Sourcing, Internet Facilitates Flexible Collaboration

almost 25 years ago

Inside Washington: Biotechnology in the Limelight, the Year Ahead

almost 25 years ago

Your Vested Interests: The War of the West

almost 25 years ago

Statistics for Laboratory Method Comparison Studies

almost 25 years ago

From the Editor: Farewell to 2001 . . . Our Biotech Odyssey Continues

almost 25 years ago

Systematic Troubleshooting for LC/MS/MS: Part 2, Large-Scale LC/MS/MS and Automation

almost 25 years ago

Information Age Audits

almost 26 years ago

Considerations During Development of a Protein A-Based Antibody Purification Process

Related to this article

View more
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
Read more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more